Brief: Fusen Pharmaceutical Says HY Revenue RMB165.6 Mln
29/08/2022 14:55
Aug 29 (Reuters) - Fusen Pharmaceutical Co Ltd 1652.HK :
* HY REVENUE DECREASED BY APPROXIMATELY 22.7% TO
APPROXIMATELY
RMB165.6 MILLION
* HY LOSS ATTRIBUTABLE RMB7.0 MILLION VERSUS PROFIT RMB43.9
MILLION
* SEES SALES VOLUME WILL PICK UP IN SECOND HALF OF YEAR
* SEES RESEARCH AND DEVELOPMENT EXPENSES WILL INCREASE
SIGNIFICANTLY THIS YEAR
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA